Guangdong Taienkang Pharmaceutical Co., Ltd.

XSEC:301263 Stock Report

Market Cap: CN¥5.5b

Guangdong Taienkang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Guangdong Taienkang Pharmaceutical has been growing earnings at an average annual rate of 18.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 9.1% per year. Guangdong Taienkang Pharmaceutical's return on equity is 7.7%, and it has net margins of 20.3%.

Key information

18.1%

Earnings growth rate

5.6%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate9.1%
Return on equity7.7%
Net Margin20.3%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guangdong Taienkang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:301263 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2475615420664
31 Dec 2376116020663
30 Sep 2379118921264
30 Jun 2381420620957
31 Mar 2379417322450
01 Jan 2378317521540
30 Sep 2275916819429
30 Jun 2271214019025
31 Mar 2269715716425
01 Jan 2265412016626
30 Sep 2166112417731
30 Jun 2166812717432
31 Mar 2167013316532
31 Dec 2070916115731
30 Sep 2066213814833
30 Jun 2061211913330
31 Mar 205658713027
31 Dec 194965511724
30 Sep 194965610619
30 Jun 195126910520
31 Mar 19523769920
31 Dec 185147410020
30 Sep 18486719820
30 Jun 18480679720
31 Mar 18457588928
31 Dec 17450558924
30 Sep 17430438719
30 Jun 17408358614
31 Mar 1737831900
31 Dec 1636728900
30 Sep 1638238900
30 Jun 1639849900
31 Mar 1638445820
31 Dec 1537042750
30 Sep 1533736650
30 Jun 1530429560
31 Mar 1530535550
31 Dec 1430440520
31 Dec 1328048440

Quality Earnings: 301263 has a high level of non-cash earnings.

Growing Profit Margin: 301263's current net profit margins (20.3%) are lower than last year (21.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301263's earnings have grown by 18.1% per year over the past 5 years.

Accelerating Growth: 301263's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301263 had negative earnings growth (-11%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 301263's Return on Equity (7.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.